Patent intelligence · US
US 7566719
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
Patent details — US 7566719
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 28, 2009
- Expiration
- Jul 23, 2029
- Applicant
- Enanta Pharmaceuticals, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K38/212, A61K38/215, A61P
Quick answer
US 7566719 (Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors) is held by Enanta Pharmaceuticals, Inc.. Status: granted. Granted Jul 28, 2009. Expires Jul 23, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K38/212, A61K38/215, A61P, A61P31/12, A61P31/14
More from Enanta Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384753
17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
granted -
US 12358921
Antiviral heterocyclic compounds
granted -
US 12297209
Benzodiazepine derivatives as RSV inhibitors
granted -
US 12281140
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
granted -
US 12268694
Combination pharmaceutical agents as RSV inhibitors
granted -
US 12264159
Functionalized heterocycles as antiviral agents
granted -
US 12162857
Antiviral compounds
granted -
US 12145941
Heterocyclic antiviral agents
granted
Frequently asked questions
What is US patent 7566719?
US 7566719 (Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors) is held by Enanta Pharmaceuticals, Inc.. Status: granted. Granted Jul 28, 2009. Expires Jul 23, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7566719?
Enanta Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 218 pharmaceutical patents for this assignee.
When does US 7566719 expire?
Our index shows an expiration date of Jul 23, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.